Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

NCT06538181

Status	RECRUITING
Phase	Phase 1
Sponsor	Washington University School of Medicine
Enrollment	15 participants

Key Eligibility Criteria

Inclusion (30)

- Patients must have UBA1 mutation with a variant allele frequency (VAF) of e 2% detected on a next generation sequencing panel and have at least one of the following current or past clinical manifestation of VEXAS syndrome, as determined by the attending physician:
- skin rash
- vasculitis
- chondritis
- ocular/orbital inflammation (e.g., uveitis/iritis, episcleritis)

... and 25 more (see full listing online)

Exclusion (15)

- Prior use of pacritinib.
- Use of another JAK inhibitor within 28 days of C1D1 of pacritinib.
- Currently receiving any other investigational agents. Patients may be eligible after 28 day washout.
- Thrombotic events (arterial or venous) within 60 days prior to enrollment.
- Any recent clinically significant bleeding within at least 7 days prior to enrollment.

... and 10 more (see full listing online)

Locations (1 total)

Washington University School of Medicine, St Louis, Missouri, United States